Text Size

Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Michael Vaezi, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT01204931
First received: September 13, 2010
Last updated: March 12, 2012
Last verified: February 2012
History of Changes
  Purpose

Gastroesophageal reflux disease (GERD) is currently defined as "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications". Doctors often diagnose and treat GERD based on symptoms of heartburn and regurgitation. In recent years, the prevalence of partial or non-response to Proton Pump Inhibitors (PPI) has increased resulting in diagnostic testing with esophagogastroduodenoscopy (EGD) or ambulatory pH monitoring. Most patients do not have endoscopic evidence for reflux. Thus, in this group pH monitoring has emerged as an important physiologic test to determine the degree of esophageal acid exposure and to assess the association between patients' persistent symptoms and acid reflux events. The aims of this study are to assess the sensitivity and specificity of symptom associated indices and determine the best parameter for predicting GERD from a list of conventional pH measurement findings.


Condition
Gastroesophageal Reflux Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Can We Predict Who Has GERD? Systematic Evaluation of Role of pH Monitoring and the Specific Physiologic pH Parameters in Defining GERD, Bravo, Impedence and SISAP

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Symptom Index (SI) and Symptom Associated Probability (SAP) [ Time Frame: Following esophagogastroduodenoscopy (EGD) and 48-hr-wireless pH monitoring ] [ Designated as safety issue: No ]
    Assess the sensitivity and specificty of symptom association indices (SI and SAP)regarding gastroesophageal reflux disease (GERD)

  • Predicting gastroesophageal reflux disease (GERD) [ Time Frame: Following esophagogastroduodenoscopy (EGD) and 48-hr-wireless pH monitoring ] [ Designated as safety issue: No ]
    Determine the best parameter for predicting gastroesophageal reflux disease (GERD) from a list of conventional pH measurement findings.


Estimated Enrollment: 210
Study Start Date: November 2010
Estimated Study Completion Date: December 2012
Groups/Cohorts
Gastroesophageal Reflux Disease (GERD) Cases

Erosive disease - presence of esophageal mucosal injuries documented endoscopically.

Non-erosive disease - normal esophagogastroduodenoscopy with symptoms
Control Group
normal subjects without symptoms of gastroesophageal reflux disease (GERD)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Adult subjects presenting to Vanderbilt University Medical Center Gastroenterology outpatient clinic with symptoms consistent with gastroesophageal reflux disease (GERD)

Criteria

Inclusion Criteria:

  • Male and female subjects ages 18 or older
  • Presenting to the Vanderbilt GI outpatient clinic with symptoms of GERD
  • Undergoing upper endoscopy and wireless pH monitoring (standard of care)
  • Erosive disease: presence of esophageal mucosal injuries documented
  • Non-erosive disease: normal esophagogastroduodenoscopy (EGD) with symptoms
  • Control group: normal subjects without symptoms of GERD

Exclusion Criteria:

  • Anti-reflux therapy within 7 days prior to the pH study
  • Previous neck, esophagus, or stomach surgery
  • Major motility disorders
  • Previous neck, esophagus, or stomach cancer or radiations
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01204931

Locations
United States, Tennessee
Vanderbilt University Medical Center GI Outpatient Clinic
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Michael Vaezi, MD, PhD Vanderbilt University
  More Information

No publications provided

Responsible Party: Michael Vaezi, Medical Director, Vanderbilt University
ClinicalTrials.gov Identifier: NCT01204931     History of Changes
Other Study ID Numbers: GERD SISAP
Study First Received: September 13, 2010
Last Updated: March 12, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
reflux
gastroesophageal reflux disease
GERD

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
 Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 18, 2013